We once praised the American Diabetes Association’s courage. How things have changed The ADA must take accountability for a self-made mess

https://www.statnews.com/2026/07/31/american-diabetes-association-ada-police-apology-independence/ By Adam Marcus and Ivan OranskyJuly 31, 2026 Marcus is the editorial director of the Center for Scientific Integrity, the parent nonprofit of Retraction Watch, and senior editorial director of primary care at Medscape. Oransky is the executive director of the center and distinguished journalist in residence at New York University’s Arthur Carter Journalism Institute.

Trump administration revises rebate pilot for 340B drug discount program, angering hospitals HRSA says pilot will improve transparency by providing greater visibility into 340B transactions

https://www.statnews.com/pharmalot/2026/07/31/trump-administration-revises-rebate-pilot-drug-discount-program-hospitals/ By Ed SilvermanJuly 31, 2026 Pharmalot Columnist, Senior Writer

Syphilis spreads while researchers contend with federal constraints and a drug shortage End to cross-border collaboration makes infections easier to miss By Eric BoodmanJuly 31, 2026

https://www.statnews.com/2026/07/31/syphilis-drug-shortage-case-study-san-diego-patient-researcher-advocate/

Hiroshima at 81: America’s new nuclear bomb, a buried Iranian target, and a question no one wants to ask Henry Miller | July 30, 2026

https://geneticliteracyproject.org/2026/07/30/hiroshima-at-81-americas-new-nuclear-bomb-a-buried-iranian-target-and-a-question-no-one-wants-to-ask/ August 6 is one of the most consequential and emotional anniversaries for Americans, our World War II allies, and Japan—each for different reasons. The Manhattan Project—which developed the two atomic bombs dropped on Hiroshima and Nagasaki in Japan in 1945—was a monumental scientific and technological achievement. The bombs ended the war and saved millions of lives of combatants and civilians.

Bowing to Congressional pressure, Kennedy reverses himself and releases $600 million that helps developing countries buy and distribute vaccines Carmen Paun | Politico | July 30, 2026

https://geneticliteracyproject.org/2026/07/30/bowing-to-congressional-pressure-kennedy-reverses-himself-and-releases-600-million-that-helps-developing-countries-buy-and-distribute-vaccines/ The departments of State and Health and Human Services confirmed [on July 29, 2026] they are releasing $600 million Congress appropriated to an international partnership that helps developing countries buy and distribute vaccines.

After muzzling RFK, Jr. over autism-vaccine conspiracy theories, Trump defies aides to push scares again Melody Schreiber | The Guardian | July 30, 2026

https://geneticliteracyproject.org/2026/07/30/after-muzzling-rfk-jr-over-autism-vaccine-conspiracy-theories-trump-defies-aides-to-push-scares-again/

Fear, science, and the law: If talc powder is unlikely to cause cancer and J&J was winning in court, why did it pay more than $5.5 billion to settle? Surya Prakash Josyula | Telugu Times | July 30, 2026

https://geneticliteracyproject.org/2026/07/30/fear-science-and-the-law-if-talc-powder-is-unlikely-to-cause-cancer-and-jj-was-winning-in-court-why-did-it-pay-more-than-5-5-billion-to-settle/ It is one of the strangest corporate stories in recent history. Johnson & Johnson won most of the major talc cases that went to trial. Yet, after fighting for nearly 12 years, the healthcare giant agreed to pay $5.5 billion to settle the remaining lawsuits.

AI-generated physicians promoting bogus cures and worthless supplements surge on social media Joe Pinner | The Guardian | July 31, 2026

https://geneticliteracyproject.org/2026/07/31/ai-generated-physicians-promoting-bogus-cures-and-worthless-supplements-surge-on-social-media/ Misleading health claims online pose a “huge danger to public safety”, experts have warned, after research has shown that AI-generated doctors are gaining millions of views on TikTok by spreading dubious health advice.

Climate scientists claim conservative activists are promoting ‘lies’ that Europe’s summer heatwaves are far from unusual Estelle Nilsson-Julien, Tamsin Paternoster | Euronews | July 31, 2026

https://geneticliteracyproject.org/2026/07/31/climate-scientists-claim-conservative-activists-are-promoting-lies-that-europes-summer-heatwaves-are-far-from-unusual/ From debunking claims that cold winters do not act as proof that global warming is fake to allegations that the climate changes naturally and so mankind is not to blame, scientists have spent decades proving the very existence of the climate crisis.

How Kennedy and his family could pocket millions from Merck’s $50 million vaccine injury settlement that he oversaw Kate Gibson | CBS News | July 31, 2026

https://geneticliteracyproject.org/2026/07/31/how-kennedy-and-his-family-could-pocket-millions-from-mercks-50-million-vaccine-injury-settlement-that-he-oversaw/ Kennedy for years has earned referral fees from Wisner Baum, a Los Angeles personal injury law firm that is currently suing Merck, alleging the pharmaceutical giant failed to properly warn the public about risks from its vaccine against human papillomavirus (HPV), Gardasil ….

Viewpoint: Are the U.S. and Europe headed towards a repudiation of agricultural biotechnology red tape? Emily Bass | July 28, 2026

Viewpoint: Are the U.S. and Europe headed towards a repudiation of agricultural biotechnology red tape? Emily Bass | July 28, 2026 https://geneticliteracyproject.org/2026/07/28/viewpoint-are-the-u-s-and-europe-headed-towards-a-repudiation-of-agricultural-biotechnology-red-tape/ 2026 may well be remembered as the year global agriculture began to untangle itself from decades of precautionary red tape. Earlier this year, the agricultural biotechnology landscape shifted in two places that have long defined opposite poles of the regulatory debate: the European Union, historically the home of exceedingly precautionary biotech rules, and the United States, a pro-innovation leader now eyeing a massive regulatory overhaul.

FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory, and Submission Updates Tuesday, September 29, 2026 AGENDA

https://www.fda.gov/media/193623/download?utm_medium=email&utm_source=govdelivery Join SBIA as FDA shares the latest updates on registration and listing submissions, including current validation rules, and walks through the evolving regulatory requirements and compliance framework that shape how industry engages with these processes. We'll also dive into compliance strategies for drug amount reporting requirements — a great opportunity to ask questions and hear directly from those working at the forefront of these issues. FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates September 29, 2026 https://www.fda.gov/drugs/news-events-human-drugs/fdas-drug-registration-and-listing-workshop-compliance-regulatory-and-submission-updates-09292026?utm_medium=email&utm_source=govdelivery

Expedited IND Pilot Program Educational Webinar for Stakeholders August 6, 2026

https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/expedited-ind-pilot-program-educational-webinar-stakeholders-08062026?utm_medium=email&utm_source=govdelivery Expedited IND Pilot Program Educational Webinar for Stakeholders August 6, 2026, 9:00 a.m. - 10:00 a.m. ET The Food and Drug Administration is announcing an educational webinar on a proposal to establish the Expedited Investigational New Drug (IND) pilot program, a new program meant to accelerate the time from drug identification to first-in-human (FIH) clinical trial. The potential pilot program which would establish a network of qualified research institutions, such as academic medical centers (AMCs), healthcare networks (HNs), contract research organizations (CROs), regulatory advisors, and/or other research or third-party review organizations (collectively called Qualified Research Institutions, or “QRIs”), who would partner with sponsors to develop and review protocols for FIH clinical trials intended for a IND submission to FDA. FDA is holding this webinar to clarify the intent behind the program, the purpose of the RFI, and answer specific stakeholder questions that might influence your feedback on the RFI. Submit Comments Comments on the Expedited Investigational New Drug Pilot Program must be submitted on or before 11:59 p.m. Eastern Time at the end of August 24, 2026. Submit electronic comments on https://www.regulations.gov to docket FDA-2026-N-4699. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date. For additional information, see Federal Register :: Expedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Period. https://unblock.federalregister.gov/

Learning from a decade of progress in amyloidosis The Lancet +... + +

Learning from a decade of progress in amyloidosis The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10553/PIIS0140-6736(26)X2028-1 What can psychiatrists expect from the next DSM? Niall Boyce https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01077-9/abstract?dgcid=raven_jbs_etoc_feature_lancet Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions Giada Bianchi, MDa,b Send email to giada_bianchi@dfci.harvard.edu ∙ Prof Vaishali Sanchorawala, MDc ∙ Prof Ashutosh Wechalekar, MDd ∙ Martha Grogan, MDe ∙ Sarah A M Cuddy, MDa,b,f ∙ Prof Giampaolo Merlini, MD https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00302-8/abstract?dgcid=raven_jbs_etoc_feature_lancet

Vision 2040 in Japan: renewing UHC through community-based health care and health security The Lancet Regional Health – Western Pacific +... + +

https://www.thelancet.com/journals/lanwpc/issue/vol72nonull/PIIS2666-6065(26)X2005-3 Japan's health system toward 2040: structural challenges and a renewed social contract Lisa Yamasakia,b ∙ Haruka Sakamotoc ∙ Hideki Hashimotod ∙ Naoki Kondoe ∙ Osamu Kuniif ∙ Yusuke Tsugawag ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00124-0/fulltext?dgcid=raven_jbs_etoc_feature_lanwpc Comparison of sitafloxacin monotherapy versus doxycycline plus rifampicin for acute uncomplicated human brucellosis: a multicenter, randomized, open-label, non-inferiority trial Chunmei Qua,b,f,g ∙ Qingqing Xuc,f,g ∙ Tianyi Wua,b ∙ Minhe Xud ∙ Xia Gaod ∙ Zhongrong Lud ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00111-2/fulltext?dgcid=raven_jbs_etoc_feature_lanwpc

Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts July 2026 ++

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilar-and-interchangeable-biosimilar-products-considerations-container-closure-systems-and?utm_medium=email&utm_source=govdelivery FDA Issues Draft Guidance for Industry, “Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts” Today, FDA released a draft guidance for industry “Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts.” In this draft guidance, FDA outlines its recommendations for proposed biosimilar and interchangeable biosimilar products regarding the development of container closure systems (e.g., vials) and device constituent parts of combination products (e.g., delivery devices that contain the biological product such as prefilled syringes and autoinjectors). This draft guidance expands on and clarifies the Agency’s recommendations and expectations regarding the development of delivery devices and container closure systems described in Q.I.4 of the guidance for industry titled “Questions and Answers on Biosimilar Development and the BPCI Act” and the guidance for industry titled “Considerations in Demonstrating Interchangeability With a Reference Product.” Available guidance regarding the development of delivery devices and container closure systems was limited in scope and did not provide detailed recommendations regarding the human factors related considerations for proposed biosimilar and interchangeable biosimilar products. This draft guidance addresses these gaps and describes a framework for the types of data and information that may be necessary to support licensure as a biosimilar or interchangeable biosimilar product. This draft guidance supports FDA’s efforts to promote competition, reduce biosimilar and interchangeable biosimilar development costs, decrease regulatory burden, and increase patient access to biologic medications while ensuring that differences in container closure systems or devices do not compromise safety or effectiveness. This action also relates to FDA's BsUFA III commitment to issue guidance on this topic. For instructions on how to submit comments on the draft guidance, see the Federal Register Notice. For more information about biosimilars visit: www.fda.gov/biosimilars Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry March 2026 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-biosimilar-development-and-bpci-act?utm_medium=email&utm_source=govdelivery

Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Guidance for Industry July 2026 ++

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-adhesion-transdermal-and-topical-delivery-systems-andas On August 3rd, the Food and Drug Administration (FDA) will publish a final and revised draft guidance related to the design and conduct of studies for evaluating transdermal and topical delivery systems (TDS) submitted in supported of abbreviated new drug applications (ANDAs). These publications, which apply to TDS products submitted in ANDAs, include the following: The final guidance for industry entitled, “Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs.” Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry | FDA This guidance finalizes the draft guidance for industry of the same title which was announced in the Federal Register on April 13, 2023 (88 FR 22456). FDA received no comments on the revised draft guidance (Revision 2) and, thus, no comments were considered before publication of this guidance. This final guidance provides recommendations for the design and conduct of studies evaluating the adhesion performance of a transdermal or topical delivery system (collectively referred to as TDS). Depending on the objectives of a generic TDS product development program, applicants may choose to evaluate TDS adhesion in studies performed to evaluate TDS adhesion only, or in studies performed with a combined purpose (e.g., for the simultaneous evaluation of adhesion and bioequivalence (BE) with pharmacokinetic endpoints). FDA recommends that applicants consult this guidance in conjunction with any relevant product-specific guidances for industry when considering the design and conduct of studies that may be appropriate to support the BE of a proposed generic TDS product to its reference listed drug and/or reference standard product. FDA also recommends that an applicant who seeks to use an alternative approach to FDA’s recommendations for the design and conduct of studies evaluating the adhesion performance of a TDS contact the Agency to discuss the proposed alternative approach to evaluate adhesion performance for that particular drug product. As part of the Drug Competition Action Plan, FDA is publishing this final guidance to increase competition in the marketplace for prescription drugs, facilitate the entry of high-quality and affordable generic drugs, and improve public health. This guidance finalizes the draft guidance for industry of the same title issued on April 13, 2023. This final guidance assists applicants with the design and conduct of studies evaluating the adhesion performance of a TDS by providing clear information that will reduce duplicative efforts, regulatory delays, and process uncertainties for industry. It also streamlines FDA's application review process, resulting in efficient and timely reviews. By saving time and resources that lead to faster approval of generic products, the American public will see more treatment options and cost savings. The revised draft guidance for industry entitled, “Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs.” Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs | FDA This revised draft guidance provides recommendations for the design and conduct of studies to evaluate the in vivo skin irritation (and sensitization, if applicable) potential of a proposed transdermal or topical delivery system (collectively referred to as TDS). The recommendations in this revised draft guidance relate to studies submitted in support of an ANDA. The revised draft guidance is intended to clarify FDA’s recommendations and expectations related to in vivo skin irritation and in vivo combined skin irritation and sensitization studies. As part of the Drug Competition Action Plan, FDA is publishing this revised draft guidance to increase competition in the marketplace for prescription drugs, facilitate the entry of high-quality and affordable generic drugs, and improve public health. This revised draft guidance replaces the April 2023 draft guidance of the same name. This revised draft guidance assists applicants by providing clear information that will reduce duplicative efforts, regulatory delays, and process uncertainties for industry, as well as time spent by FDA reviewing applications. By saving time and resources that lead to faster approval of generic products, providing the American public with more treatment options and cost savings. Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry July 2026 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas?utm_medium=email&utm_source=govdelivery

Ex-Mayo Exec Sues, Says She Was Fired for Whistleblowing on AI Security, Privacy Randy Dotinga

https://www.medscape.com/viewarticle/ex-mayo-exec-sues-says-she-was-fired-whistleblowing-ai-2026a1000ps1?src= A former director who oversaw research at the Mayo Clinic accuses the healthcare system of retaliation after she raised the alarm about “fundamental lapses” in evaluating AI tools for patient care and research. https://www.medscape.com/index/list_15056_0

Manufacturers Report $2.6 Billion in Open Payments to Physicians, but Product Details Remain Murky Steph Weber

https://www.medscape.com/viewarticle/manufacturers-report-2-6-billion-open-payments-physicians-2026a1000pxt Drug and medical device makers reported approximately $2.6 billion in payments to more than 665,000 physicians through the Open Payments program in 2025, according to a new analysis of federal data. The manufacturers paid an additional $1.3 billion to teaching hospitals and nonphysician practitioners, bringing total spending to about $3.9 billion, an 18.4% increase from the previous year.

US Senate Panel Advances Trump CDC Pick Schwartz Ahmed Aboulenein

https://www.medscape.com/s/viewarticle/us-senate-panel-votes-advance-nomination-trump-cdc-pick-2026a1000q0v WASHINGTON, July 30 (Reuters) - The U.S. Senate health committee voted on Thursday to advance the nomination of President Donald Trump's pick for CDC director ⁠Dr. Erica Schwartz, handing his administration a rare win after repeated failed attempts to fill top health posts.

Is It Ethical for Doctors to Hawk Products in the Office? Lambeth Hochwald

https://www.medscape.com/viewarticle/it-ethical-doctors-hawk-products-office-2026a1000q0w Your patient is checking out at the dermatologist’s office. Copay? Check. Next appointment? Check. Can we show you our skincare supplements? Come again? For some physicians, the prospect of selling vitamins, supplements, ointments, or skincare products in the office may make sense: It’s easy to explain the benefits of a product when it’s on hand, and it’s convenient for patients to buy what their doctor recommends — on the way out the door.

Doctors Aren’t Asking for More Money; They’re Asking for Their Lives Back Jennifer Nelson

https://www.medscape.com/viewarticle/doctors-arent-asking-more-money-theyre-asking-their-lives-2026a1000p4t?ecd=WNL_physrep_260731_MSCPEDIT_dc-mental-health_etid8553101&uac=148436CN&impID=8553101 Nearly 6 in 10 physicians recently surveyed said they’d be willing to take a pay cut in exchange for better work-life balance — a finding that may say as much about the state of medicine as any burnout statistic.

Europe’s tentative embrace of agricultural gene editing could revolutionize food production and health in Asia Arif Hossain | Dhaka Tribune | July 28, 2026

https://geneticliteracyproject.org/2026/07/28/europes-tentative-embrace-of-agricultural-gene-editing-could-revolutionize-food-production-and-health-in-asia/

Prioritizing AI, robotics, and nuclear energy: Trump administration is guiding research funding away from independent universities to private companies Christopher Flavelle, Sheryl Gay Stolberg | New York Times | July 28, 2026

https://geneticliteracyproject.org/2026/07/28/prioritizing-ai-robotics-and-nuclear-energy-trump-administration-is-guiding-research-funding-away-from-independent-universities-to-private-companies/

Viewpoint: RFK, Jr.’s depressingly misguided (and litigator-funded) crusade against antidepressants Aaron Carroll | Washington Post | July 28, 2026

https://geneticliteracyproject.org/2026/07/28/viewpoint-rfk-jr-s-depressingly-misguided-and-litigator-funded-crusade-against-antidepressants/

The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List July 28, 2026 By Charles D. Snow & Karla L. Palmer & Mary Bass —

https://www.thefdalawblog.com/2026/07/the-peptide-l-wave-rolls-on-pcac-adds-two-more-bulk-drug-substances-for-the-503a-list/?utm_source=rss&utm_medium=rss&utm_campaign=the-peptide-l-wave-rolls-on-pcac-adds-two-more-bulk-drug-substances-for-the-503a-list Well, don’t say we didn’t tell you what was coming. Day 2 of the Pharmacy Compounding Advisory Committee (PCAC or the Panel) Meeting (mostly) followed in the footsteps and at the pace of Day 1 (see our prior coverage of Day 1). Over the course of the day, the Panel worked through three more nominated peptides for possible inclusion on the Section 503A bulk drug substances list, ultimately recommending two—Epitalon and Semax—for inclusion, while declining to recommend Emideltide (the delta sleep-inducing peptide, aka “DSIP”). Was the DSIP “no-vote” the sacrificial lamb here? As on Day 1, the real drama was less in the vote counts than in the recurring, and still-unresolved, question that FDA pressed from the outset: When a prescriber writes a prescription for one of these peptides, does anyone actually know what the patient is receiving?

Number of Measles Cases Roars Past Last Year's Total As Vaccine Hesitancy Takes Hold

Number of Measles Cases Roars Past Last Year's Total As Vaccine Hesitancy Takes Hold A little more than halfway through the year, the United States has already confirmed more cases — 2,318 — than it had in 2025. Public health experts say a full-throated vaccination push at the national level would stem the tide in cases but acknowledge that seems unlikely under the current administration. Plus, the latest on rising cyclosporiasis cases. https://kffhealthnews.org/morning-briefing/monday-july-27-2026/

Cyclospora Boosts Fears That Worse Foodborne Outbreaks Are Ahead

Cyclospora Boosts Fears That Worse Foodborne Outbreaks Are Ahead The recent outbreak of a foodborne parasite sickened thousands and hospitalized hundreds across the U.S. before federal investigators identified the suspected source. Food safety experts say cuts to the public health system hobbled the response — and that the next outbreak could be much worse. ( Kate Wells and Stephanie Armour , 7/28 ) https://kffhealthnews.org/latest-morning-briefing/

Trump Administration Demands Hospitals Share Emergency Room Records By Amanda Seitz, Maia Rosenfeld, and Darius Tahir July 27, 2026

https://kffhealthnews.org/health-industry/cpsc-consumer-product-safety-commission-trump-er-injury-data-grab-neiss-konza/ A tiny federal agency tasked with protecting the public from injuries caused by lawn mowers and coffeemakers is demanding that some of the nation’s biggest health systems turn over detailed, personally identifiable medical records of all patients who seek help at their emergency rooms.

Federal Loan Caps Add Barriers — And Likely Debt — for Healthcare Students

https://kffhealthnews.org/news/wamu-health-hub-federal-loan-caps-healthcare-careers-student-debt/ KFF Health News: Federal Loan Caps Add Barriers — And Likely Debt — For Healthcare Students The federal government is capping the amount graduate students can borrow. The Department of Education says the new rules are designed to help curb student debt and pressure schools to lower tuition. But some loan experts fear those good intentions could leave many at the mercy of private lenders with higher interest rates. Saddling healthcare graduate students with pricier debt burdens can narrow their career choices. (Sausser, 7/28)

Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California By Annie Sciacca July 28, 2026

https://kffhealthnews.org/elections/newsom-california-teacher-paid-maternal-pregnancy-leave-reversal/ California public school teacher Mollie Blustein planned her pregnancy so that her daughter would arrive during summer break. But when the elementary school teacher went into premature labor and delivered her baby two weeks before the end of school, she faced another stressor: a huge pay cut. KFF Health News: Newsom Reverses On Long-Sought Paid Leave Benefit For Teachers In California California public school teacher Mollie Blustein planned her pregnancy so that her daughter would arrive during summer break. But when the elementary school teacher went into premature labor and delivered her baby two weeks before the end of school, she faced another stressor: a huge pay cut. The majority of California’s roughly 300,000 teachers don’t have access to the state-funded paid leave program that most new parents in the private sector do. Instead, many local school districts deduct the cost of a substitute teacher from educators’ pay during parental leave. (Sciacca, 7/28)

Cyclospora Boosts Fears That Worse Foodborne Outbreaks Are Ahead By Kate Wells and Stephanie Armour July 28, 2026

https://kffhealthnews.org/public-health/cyclospora-outbreak-foodborne-monitoring-cdc-fda-trump-cuts-michigan/ The recent outbreak of a foodborne parasite sickened thousands and hospitalized hundreds across the U.S. before federal investigators identified the suspected source. Food safety experts say cuts to the public health system hobbled the response — and that the next outbreak could be much worse.

How Many Uninsured Are in the Coverage Gap and How Many Could be Eligible if All States Adopted the Medicaid Expansion? Authors: Sammy Cervantes, Clea Bell, Jennifer Tolbert, and Anthony Damico Published: Jul 27, 2026

https://www.kff.org/medicaid/how-many-uninsured-are-in-the-coverage-gap-and-how-many-could-be-eligible-if-all-states-adopted-the-medicaid-expansion/ This analysis estimates that 1.4 million uninsured individuals in the ten states without Medicaid expansion, including many working adults, people of color, and those with disabilities, remain in the "coverage gap," ineligible for Medicaid or for tax credits that would make coverage affordable through the Affordable Care Act's Marketplaces.

Donor Government Funding for HIV Drops by $2.1 Billion in 2025 Due to Declines in Funding from the United States, Marking Largest Annual Decrease Since Scale-up for the HIV Response Began Published: Jul 27, 2026

https://www.kff.org/global-health-policy/donor-government-funding-for-hiv-drops-by-2-1-billion-in-2025-due-to-declines-in-funding-from-the-united-states-marking-largest-annual-decrease-since-scale-up-for-the-hiv-response-began/ Donor government funding to combat HIV in low- and middle-income countries fell by $2.1 billion in 2025, a 25% decrease from the previous year, according to a new report by KFF and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Total disbursements dropped to $6.2 billion in 2025, down from $8.3 billion in 2024, marking the largest single-year decline since donor funding scale-up

Donor Government Funding for HIV in Low- and Middle-Income Countries in 2025 Authors: Adam Wexler, Jennifer Kates, and Stephanie Oum Published: Jul 27, 2026

https://www.kff.org/global-health-policy/donor-government-funding-for-hiv-in-low-and-middle-income-countries-in-2025/ This report provides an analysis of donor government funding to address the HIV response in low- and middle-income countries in 2025, the latest year available, as well as trends over time. It includes both bilateral funding from donors and their multilateral contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), UNITAID, and Joint United Nations Programme on HIV/AIDS (UNAIDS).

KFF Health Tracking Poll: Ebola & Pandemic Preparedness Authors: Lunna Lopes, Isabelle Valdes, Audrey Kearney, Mardet Mulugeta, and Liz Hamel Published: Jul 28, 2026

https://www.kff.org/public-opinion/kff-health-tracking-poll-ebola-pandemic-preparedness/ Much of the public has yet to form an opinion on the U.S. government’s response to the Ebola outbreak in the Democratic Republic of the Congo, this poll finds. Four in ten adults say the U.S. is less prepared for a pandemic now than it was in 2020.

How Has ACA Marketplace Enrollment Changed Across States in 2026? Authors: Justin Lo, Matt McGough, and Cynthia Cox Published: Jul 28, 2026

https://www.kff.org/affordable-care-act/how-has-aca-marketplace-enrollment-changed-across-states-in-2026/ Following several years of rapid enrollment growth in the Affordable Care Act (ACA) Marketplaces that corresponded with temporary enhanced premium tax credits, enrollment fell for the first time in seven years in 2026, when those tax credits expired. Every state except for New Mexico saw a drop in ACA Marketplace enrollment from 2025 to 2026. State-based Marketplaces that run their own enrollment platforms, including those that partially offset the expiring federal enhanced tax credits, generally…

Comparing U.S. Ebola Outbreak Response Capabilities and Practices Over Time Authors: Josh Michaud and Jennifer Kates Published: Jul 28, 2026

https://www.kff.org/global-health-policy/comparing-u-s-ebola-outbreak-response-capabilities-and-practices-over-time/?utm_campaign=KFF-Global-Health-Policy&utm_medium=email&_hsenc=p2ANqtz-_4_mg6ApbNggnN2nnWRA5ZfKhpuNEA7dN6Q1w7JMVmr06wF6MPgCw3KAjXVrDHBwjBsA9X6g2tpDMRm74cSw-O3tOscw&_hsmi=430464226&utm_content=430464226&utm_source=hs_email Analysis Compares the U.S. Response to the Current Ebola Outbreak to Past Ones A new KFF analysis compares the Trump administration’s response to the ongoing Ebola outbreak in the Democratic Republic of Congo – the most significant international infectious disease outbreak of its second term – to earlier outbreaks during the Obama administration and first Trump administration. While the current administration significantly altered the structure of the U.S. global health response, the analysis shows that the speed of the response is on par with the prior two outbreaks. In addition, the U.S. pledge of $375 million during the first two months of the current outbreak already exceeds funding levels during the prior outbreaks. At the same time, there are still many unknowns about the U.S. response and there are distinctions from the past, including lack of formal coordination with the World Health Organization, significant changes in U.S. global health efforts, including funding reductions, and a more restrictive domestic border protection approach. The analysis includes a detailed side-by-side comparison of the U.S. response to each of the three Ebola outbreaks, including funding levels, staff deployments, research support, communications practices, multilateral engagement, domestic border protection measures, and organizational structure. It also includes background on the scope of the three outbreaks and pre-existing U.S. global health engagement in affected countries. KFF is also releasing new polling that shows much of the public has yet to form an opinion on the U.S. government’s response to the outbreak. When it comes to preventing an Ebola outbreak in the U.S., people are more likely to say that the U.S. is not doing enough (38%) than say it is doing enough (23%). This reflects a wide partisan gap in perceptions, with a majority of Democrats saying the U.S. is not doing enough to prevent an outbreak in the U.S. Republicans are more than twice as likely to say the government is doing enough than not doing enough, while the reverse is true for independents. The poll also gauges the public’s views on the nation’s preparedness for a major pandemic. Four in 10 adults (40%) say the U.S. is less prepared now than it was in 2020 when COVID-19 hit. That is up from one in four (26%) who said the same in January 2025 shortly before the start of President Trump’s second term. This again reflects a wide partisan divide. Contact: Craig Palosky | 202.654.1369 | CraigP@kff.org

Business of Medicine +...

https://www.medscape.com/businessmedicine FemTech’s Biggest Test: Can It Deliver on Its Promise? Maria Cristina Valsecchi https://www.medscape.com/viewarticle/femtechs-biggest-test-can-it-deliver-its-promise-2026a1000pmp July 28, 2026 For decades, the hormonal fluctuations that characterize the female reproductive cycle have been viewed as a confounding factor, contributing to the exclusion or underrepresentation of women in preclinical and clinical research. Today these same fluctuations are increasingly recognized as a valuable source of information about women’s overall health.

Office of New Drugs Standard Safety Tables and Figures for New Drug and Biologic Applications June 23, 2026

Office of New Drugs Standard Safety Tables and Figures for New Drug and Biologic Applications https://www.fda.gov/drugs/news-events-human-drugs/office-new-drugs-standard-safety-tables-and-figures-new-drug-and-biologic-applications-06232026?utm_medium=email&utm_source=govdelivery

FDA/Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway September 23 - 24, 2026

https://www.fda.gov/drugs/news-events-human-drugs/fdacenter-research-complex-generics-crcg-workshop-navigating-glp-1-generic-drug-pathway-09232026?utm_medium=email&utm_source=govdelivery Are you looking to deepen your understanding of regulatory science, innovative analytical approaches, and development strategies for generic GLP-1 drug products? This 2-day hybrid workshop brings together FDA, industry, consulting groups and academic experts to address regulatory challenges and to explore the latest scientific advancements shaping the development of generic GLP-1 products across diverse therapeutic areas. Through a series of presentations and interactive discussions, participants will examine regulatory pathways and clinical contexts for generic GLP-1 products, explore characterization and sameness demonstration strategies, and delve into recombinant peptide manufacturing and host cell impurity characterization and control. The program will also address critical challenges such as Product-Specific Guidance (PSG) development, bioequivalence study design and quality expectations for oral and injectable generic GLP-1 products, device user interface evaluation and considerations for supporting other design differences, and drug-device integration and submission coordination, equipping attendees with the knowledge needed to navigate the regulatory landscape. Choose your experience: Virtual: Access expert presentations and panel discussions from anywhere. In-person: Interact directly with experts from industry, consulting groups, academia and FDA to understand current practices and challenges, regulatory expectations, and emerging trends. Registration fee applies. The in-person component will take place at The Universities at Shady Grove, Rockville, MD. High-engagement scientific interactions will be facilitated through two in-person-only sessions: A session dedicated to informal networking and candid dialogue among subject matter experts about scientific and regulatory challenges for generic GLP-1 products including sections focused on: Device constituents of drug-device combination products Impurities and immunogenicity GLP-1 characterization and sameness Orally administered peptides A guided session for small groups to elucidate and work through specific challenging issues for generic GLP-1 products development and assessment. Don’t miss this opportunity to advance your expertise, network with leading professionals, and help shape the future of generics. For more information, visit https://www.complexgenerics.org/education-training/navigating-the-glp-1-generic-drug-pathway/

Oncology Center of Excellence Guidance Documents

https://www.fda.gov/about-fda/oncology-center-excellence/oncology-center-excellence-guidance-documents?utm_medium=email&utm_source=govdelivery Today, the FDA’s Oncology Center of Excellence is announcing three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs. Fewer than 5% of cancer patients currently receiving treatment are enrolled in clinical trials even though more than 70% say they are willing to participate. The guidance documents address one reason for low participation – stringent and complex clinical trial eligibility criteria. “Unnecessarily restrictive eligibility criteria may slow subject accrual, limit patients’ access to clinical trials, and lead to trial results that do not fully represent treatment effects in the patient population that will ultimately use the drug,” the three guidances say in their preambles. Each document focuses on a specific area where rigid eligibility criteria limit participation including: • Defining who is too sick to participate. The final guidance Cancer Clinical Trial Eligibility Criteria: Performance Status Guidance for Industry, IRBs, and Clinical Investigators raises questions about the use of the common yardstick known as “performance status,” a measure of how well a patient is able to perform ordinary tasks and carry out activities of daily living. Some patients may have a low performance status because cancer has made them sick, but this status could improve once the patient is enrolled in the trial, the guidance says. • Deciding when patients should be excluded if they are taking other medications. The final guidance Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications Guidance for Industry, IRBs, and Clinical Investigators encourages sponsors to consider whether time based “washout periods” are necessary between stopping one cancer drug and beginning the experimental drug and also makes some allowances for patients taking other medications. • Determining the appropriate laboratory value for test results that determine trial eligibility. The final guidance Cancer Clinical Trial Eligibility Criteria: Laboratory Values Guidance for Industry, IRBs, and Clinical Investigators discusses taking a more scientific and safety-focused approach to tests commonly used to determine whether a patient might qualify to participate in a clinical trial. The three guidance documents advance one of the goals of HHS’ Operation Trialblazer Initiative, a coordinated federal initiative designed to accelerate drug development and reclaim America’s edge in clinical research. The Trialblazer Roadmap, released in late June, tasked the FDA with Improving patient and participant access and engagement in clinical trials. The documents are part of a series of guidances developed as a result of workshops with Friends of Cancer Research and the American Society of Clinical Oncology.

FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials August 27, 2026

https://www.fda.gov/drugs/news-events-human-drugs/fda-virtual-workshop-digital-health-technologies-and-statistical-considerations-digitally-derived?utm_medium=email&utm_source=govdelivery FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials Date: Thursday, August 27, 2026; 9:30 a.m. - 3:45 pm ET The FDA is hosting a free virtual public workshop, convened by the Duke-Margolis Institute for Health Policy under a cooperative agreement with the FDA, to discuss statistical considerations for digitally-derived endpoints in clinical trials for drug and biological products. https://healthpolicy.duke.edu/events/statistical-considerations-digitally-derived-endpoints-clinical-trials

Cancer Clinical Trial Eligibility Criteria: Performance Status Guidance for Industry, IRBs, and Clinical Investigators July 2026

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-performance-status?utm_medium=email&utm_source=govdelivery

Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications Guidance for Industry, IRBs, and Clinical Investigators July 2026

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications?utm_medium=email&utm_source=govdelivery

Cancer Clinical Trial Eligibility Criteria: Laboratory Values Guidance for Industry, IRBs, and Clinical Investigators July 2026

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-laboratory-values?utm_medium=email&utm_source=govdelivery

Reduced or Waived Medical Device User Fees: Small Business Determination (SBD) Program

https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/reduced-or-waived-medical-device-user-fees-small-business-determination-sbd-program?utm_medium=email&utm_source=govdelivery FY 2026 Small Business Applications Close August 1 — FY 2027 Applications Open Immediately After If you are interested in applying to the MDUFA Small Business Determination Program, please read this important update about upcoming application deadlines. FY 2026 Deadline: August 1, 2026, at 4:00 PM ET The deadline to submit a FY 2026 MDUFA Small Business Request is 4:00 PM ET on August 1, 2026. FY 2026 determinations are effective from October 1, 2025, through September 30, 2026. Applications submitted after 4:00 PM ET on August 1, 2026, will not be accepted for FY 2026. If you plan to submit a medical device application during FY 2026 and are seeking a reduced fee or waiver, you must have your small business determination before you submit your device application. Do not submit your device application until you have received your small business determination from FDA. FY 2027 Applications Open: August 1, 2026, at 4:01 PM ET The application window for FY 2027 MDUFA Small Business Requests opens at 4:01 PM ET on August 1, 2026. FY 2027 covers October 1, 2026, through September 30, 2027. Applications submitted before 4:01 PM ET on August 1, 2026, will not be accepted for FY 2027. How to Apply All Small Business Requests must be submitted electronically through the CDRH Portal. Step-by-step instructions are available on the Reduced Medical Device User Fees: Small Business Determination (SBD) Program page. As stated in FDA's guidance, Medical Device User Fee Small Business Qualification and Determination (issued July 31, 2025), FDA accepts Small Business Requests for a given fiscal year beginning August 1 of the prior year. Requests for the next fiscal year received before August 1 will not be accepted. Medical Device User Fee Small Business Qualification and Determination Guidance for Industry, Food and Drug Administration Staff and Foreign Governments July 2025 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-user-fee-small-business-qualification-and-determination?utm_medium=email&utm_source=govdelivery

Now live: The 2026 Canadian Regulatory Compliance Handbook

https://academy.delltech.com/?error=Your%20order%20has%20timed%20out.%20Please%20try%20again. Now live: The 2026 Canadian Regulatory Compliance Handbook Dell Tech’s Canadian Regulatory Compliance Handbook is now available through Dell Tech Academy. This practical guide was created to help businesses better understand Canadian compliance requirements across key product categories, including Natural Health Products, cosmetics, foods, and more. It is designed to support clearer decision-making, smoother market access, and stronger regulatory preparedness.

Expert-led eLearning to Achieve Compliance & Improve Operations

https://www.registrarcorp.com/compliance-training/?utm_campaign=food-and-beverage-cosmetics-medical-device-drugs-registrar-newsfeed-07-28-2026&utm_medium=email&_hsenc=p2ANqtz-8bwlnyVTNyGSVgXdM4H7kHhCY-o9HL5R926VxnxJnmuOHvkmFZRlD3hGgSeqzvc5PWygs4frvt6V8k_8xu_jsRdbmUWA&_hsmi=430311558&utm_content=hyperlink&utm_source=hubspot Self-paced FDA Compliance Training Explore professional training courses covering Food Safety, Cosmetics, Pharmaceuticals, and Medical Device compliance topics, including PCQI, HACCP, FSVP, and MoCRA. Designed for regulatory professionals and industry teams, these courses help support compliance with FDA and global regulatory requirements through flexible, expert-led learning.

How Medical Device Companies Can Overcome EUDAMED 2026 Registration Challenges

https://www.registrarcorp.com/blog/medical-devices/medical-device-registration/eudamed-2026-registration/?utm_campaign=food-and-beverage-cosmetics-medical-device-drugs-registrar-newsfeed-07-28-2026&utm_medium=email&_hsenc=p2ANqtz-9Ka6icstFVPpNmPlp3Jq1s5dhQ6NO7iT2Vf0Uuw_fVqQp5ppBXWnTrLw46LX1nsxYzJNvmilBggLrpCAycsDOcpeFPDw&_hsmi=430311558&utm_content=medical-device-hyperlink&utm_source=hubspot EUDAMED 2026 Deadlines Will Impact EU Market Access EUDAMED is moving toward mandatory use, with key 2026 deadlines that will directly affect medical device and IVD manufacturers selling in the European Union. Companies must complete actor registration, device data submissions, and other required records to maintain compliance under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). This article outlines the major deadlines and actions manufacturers should take now to avoid delays and maintain uninterrupted market access.

2026 FDA Food Facility Registration Renewal: What Food Exporters Need to Know

https://www.registrarcorp.com/blog/food-beverage/fda-renewal-2026-ffr-registration/?utm_campaign=food-and-beverage-cosmetics-medical-device-drugs-registrar-newsfeed-07-28-2026&utm_medium=email&_hsenc=p2ANqtz-_JxnVWw-IHkKA1HzU6GhsqnvPic1gC6U7VP-Q8NNHJlmCf737tBAPlTYuu3TlYaELcBjHv5_Ko-6zIuXYwlGKj3E_2VQ&_hsmi=430311558&utm_content=food-and-beverage-hyperlink&utm_source=hubspot FDA Food Facility Registration Renewal Opens for 2026 Food facility registration renewal is required every even-numbered year, and facilities that manufacture, process, pack, or hold food for U.S. consumption must submit their renewal between October 1 and December 31, 2026. Failure to renew can result in expired registration, shipment delays, product holds, and disruptions to U.S. market access. This article explains who must renew, key deadlines, and steps companies can take now to ensure compliance before the renewal period closes.

EU Fragrance Allergen Expansion: What the July 31, 2026 Deadline Means for Your Brand Jul 13, 2026

https://www.registrarcorp.com/blog/cosmetics/eu-fragrance-allergen-expansion-2026/?utm_campaign=food-and-beverage-cosmetics-medical-device-drugs-registrar-newsfeed-07-28-2026&utm_medium=email&_hsenc=p2ANqtz--5N1xr2Cmbgt1-bCAz5L5FGu7lqLSeZjYnKH1vICKDyOwLz45IAY4MJElYytnrEPmMYdhjMVFFUYa5QAKlOt8k3j08TA&_hsmi=430311558&utm_content=hyperlink&utm_source=hubspot EU Fragrance Allergen Deadline Arrives July 31 Beginning July 31, 2026, all new cosmetic products placed on the EU market must comply with expanded fragrance allergen labeling requirements under Regulation (EU) 2023/1545. The update increases mandatory allergen disclosures from 26 to approximately 82 substances and may require companies to update formulations, labels, Product Information Files (PIFs), Cosmetic Product Safety Reports (CPSRs), and CPNP notifications. Brands that fail to comply risk customs detentions, product recalls, and market withdrawal, making now the time to prepare for the deadline.

FDA Proposes Rule to Modernize Drug Manufacturing Registration Proposed rule would streamline registration for advanced distributed manufacturers and increase visibility into foreign drug supply sources

https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-modernize-drug-manufacturing-registration?utm_campaign=42504259-FnB%2C%20Cosmetics%2C%20Med%20Dev%2C%20Drugs%20%7C%20Newsfeed%20%7C%20Global%20%7C%202026&utm_medium=email&_hsenc=p2ANqtz-9v44-EMHC3g_teh9_yvvYv0yZj1qx3NhhAgxhl4tgyoQNO9bSE3KDBGPN1NymexqZaA8uC2MnP4FCSRHHtx6QztuCNdw&_hsmi=430311558&utm_content=429969268&utm_source=hs_email FDA has proposed a new rule that would streamline registration for distributed drug manufacturing facilities operating under a ""hub-and-spoke"" model while clarifying registration requirements for certain foreign drug manufacturers, including facilities that produce active pharmaceutical ingredients (APIs). If finalized, the rule would reduce administrative burden for innovative manufacturers while giving FDA greater visibility into global drug supply chains and upstream manufacturing activities by expanding applicability of listing requirements to more foreign drug manufactures who are not directly importing its produced products into the United States. Companies should review the proposal closely, as it signals FDA's continued focus on supply chain transparency, advanced manufacturing, and stronger oversight of foreign drug establishments.

MA Dental Benefits Are Growing, But The Data Needed For Accountability Are Not Cilia E. ZayasandDavid J. Meyers July 20, 2026

https://www.healthaffairs.org/content/forefront/medicare-advantage-dental-benefits-growing-but-data-needed-accountability-not?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-_Mz7c1GbKkQXgRibtBICyUkhFpVcg8-kJsPPynrfUrpdL6I7WuTwoGrabdJenzzjoGnboclARH6SgatjmtlGSWYw1jIg&_hsmi=430012622&utm_source=hasu Without data that support plan level evaluation, accountability for Medicare Advantage dental benefits remains aspirational rather than operational.

By Regulatory Design: Geopolitical Concentration In The US Morphine Supply Chain Marta E. WosińskaandBen Graham July 24, 2026

https://www.healthaffairs.org/content/forefront/regulatory-design-geopolitical-concentration-us-morphine-supply-chain?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-8PJQMInPYTWZnzRvPqRC4HsngjLim_PhMKlL5SiNRXR4YoWnOhh0huL-mrbJVNXghyLMcjF9_avFD9UJjwKctTbc32Zw&_hsmi=430012622&utm_source=hasu Nearly 45 years after the “80/20” rule was adopted, the upstream morphine supply chain for the US is concentrated in a single country. The rule warrants reexamination, and other policy options to diversify supply should be considered as well.

Delivering On The Promise Of Medicaid’s Policy Laboratory Lindsay AllenandKatherine Commey July 21, 2026

https://www.healthaffairs.org/content/forefront/delivering-promise-medicaid-s-policy-laboratory?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-80uxV5vVFVRCFCZYc3sF7Kj_2COpJLrg0xFP2_ajd9aGk_30I0W9XJtLQrohRi2JYJFeFs9GpQCEcLP7neXddSlvDCLg&_hsmi=430012622&utm_source=hasu The premise of Medicaid as a policy laboratory rests on generating knowledge through rigorous evaluation. Yet, too often, evaluation has functioned only as a compliance exercise. Instead, it should be driving a robust learning system.

Health Care Inflation Means Quality-Adjusted Price Growth, And Artificial Intelligence Can Reduce It Jonathan D. Ketcham July 23, 2026

https://www.healthaffairs.org/content/forefront/health-care-inflation-means-quality-adjusted-price-growth-and-artificial-intelligence?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz--9vS5OLUQuUtBmY5mzoUHsonJ1w-Y8xPvFioBqzm0uVcdRj8G7JIqN-m1VAj8paToRWH_lG5aR0kStj_vcP_rn7Z9atw&_hsmi=430012622&utm_source=hasu A response to “Why AI Will Accelerate Health Care Inflation” by David Brailer

Court Stays Major 2027 Marketplace Changes Katie Keith July 24, 2026

https://www.healthaffairs.org/content/forefront/court-stays-major-2027-marketplace-changes?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-8gUug3qWZjsG0_KxWT0yZ713D7k_XT64MSyUGcnf-MCBtgxQgf7ZREfTb1CpkxAES1kYKVd8Ii15L9R6mMjwvy1zGWmg&_hsmi=430012622&utm_source=hasu The administration is expected to appeal at least parts of the ruling, but the timing and scope of appeal is unclear. Meanwhile, HHS may offer flexibility on the current August 12 deadline for insurers to make final changes to their 2027 marketplace plans.

Why Medicare Must Negotiate Drug Prices At Launch Sarah Karlin-Smith July 22, 2026

https://www.healthaffairs.org/content/forefront/why-medicare-must-negotiate-drug-prices-launch?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-_mlVIRJtVlJiafnjoHUMBAmokP9a6yDqv4C4gDlZgLb4UH3zJXJ6m3YvkCYdAdb4ILyGl25T-gVm_ILBOk7rudRJvECQ&_hsmi=430012622&utm_source=hasu Negotiating drug prices at launch would ensure that patients and health programs get fair prices on prescription drugs at the outset, instead of first facing nearly a decade or longer of excessive prices set to maximize revenues.

HR 1 Does Not Block States From Offering Medicaid And CHIP To Lawfully Residing Children And Pregnant Women Kelly Whitener July 20, 2026

https://www.healthaffairs.org/content/forefront/hr-1-does-not-block-states-offering-medicaid-and-chip-lawfully-residing-children-and?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-_tKHl6kWBVTHXOlPnLLXhmi8Lp0fidi5TzFoG8_vWc9lBbed-cYqDk3OQ0oIOWU0jI9o9rfjZQEyZCXHq7qdA_hP_xqw&_hsmi=430012622&utm_source=hasu

The Abortion Pill Case Could End Telehealth Prescribing Carmel ShacharandAmar Kelkar July 21, 2026

https://www.healthaffairs.org/content/forefront/abortion-pill-case-could-end-telehealth-prescribing?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-_gcHPtoTDSsZnGNK-rVaQET0Q1cFo5obiQqwVndtNXMN2qsCTYL2o3LYJIR95wdIPxg50Xls7Ll1DX-Lh2X-WuU5lD_w&_hsmi=430012622&utm_source=hasu

What’s Next For Prescription Drug Affordability Boards After Amgen v. Mizner? Andrew TwinamatsikoandKatie Keith July 23, 2026

https://www.healthaffairs.org/content/forefront/s-next-prescription-drug-affordability-boards-after-amgen-v-mizner?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-_035djYVu9PJNbuaUkd0Ogpn7nHYflN44OidJvdB-jPFijx6LIkzmloakibr-UizW3-WElZcokt6eRLm3UpgO1XYURKA&_hsmi=430012622&utm_source=hasu

Health Research Funding Suddenly Cut: Dr. Aaron Carroll Explains Jeff ByersandAaron E. Carroll July 23, 2026

https://www.healthaffairs.org/do/10.1377/hp20260722.700568/full/?utm_campaign=podcast&utm_medium=email&_hsenc=p2ANqtz-8vKHmse15jTfzY5WmSLY1fATYjDhRyGgS9bzBZQERrEoBlHauWAeACnNDNUOkvpH3nguQVT0467rn-BK2Ne6Xq-1fvAQ&_hsmi=430012622&utm_content=hatw&utm_source=hasu

Corporate Consolidation And The Youth Mental Health Crisis: Evidence From Medicaid Managed Care In 2022 Authors: K. John McConnell mcconnjo@ohsu.edu, Sara Edelstein, Courtney Benjamin Wolk, Kelsey Watson, Katherine Courchaine, Stephan Lindner, and Jane M. Zhu

https://www.healthaffairs.org/doi/10.1377/hlthaff.2025.01619?utm_campaign=august+2026+issue&utm_medium=email&_hsenc=p2ANqtz-_TiKWVlDN3H-SjkTWWD_D0BGB63niWcVyre_GqZUhsXSsSxhEcErV78UdlYsfCUqLJJnzQt7JeAK5jBqMKd11zJuU2nA&_hsmi=430012622&utm_content=ahead+of+print&utm_source=hasu Medicaid managed care organizations serve as the primary vehicle for delivering behavioral health services to low-income youth. However, market consolidation has shifted enrollment toward a handful of large national parent firms. Understanding the implications of this shift is critical for identifying and closing gaps in adolescent mental health services. Using national Medicaid claims data from 2022, we examined the associations between managed care organization ownership by five major parent firms and measures of youth mental health service use and provider composition. Managed care organizations owned by large national parent firms were characterized by lower mental health screening rates and, for most firms, higher use of emergency department, inpatient, and medication-based care, including psychotropic prescribing without psychotherapy. Provider composition also varied by firm, suggesting differences in how these organizations structure their behavioral health networks, with some relying more heavily on psychiatrists and psychologists and others depending more on master’s-level therapists. The growing influence of large national parent firms in shaping behavioral health access for Medicaid-enrolled youth underscores the need for closer scrutiny of how managed care structures serve youth with significant mental health needs.

Winter Break for the "Equitable Health" Blog Group... the blogs will not be updated on July 26, 27, 28, 29, and 30, 2026... We apologize for this, but we hope you understand that we deserve a break... We will return on July 31, God willing... Many thanks to all our readers and followers (whose numbers are constantly growing)... Until then... The Editor...

Receso Invernal del grupo de blog´s de "salud equitativa"... los días 26, 27, 28, 29, y 30 de julio de 2026, los blog´s no se actualizarán... pedimos disculpas por ello, pero esperamos sepan entender que merecemos un descanso... regresaremos el 31 de julio si Dios lo permite... muchas gracias a todos los lectores y seguidores (que cada vez son más)... hasta entonces... El editor... Grupo de blog´s de “salud equitativa”, cuyo titular es Víctor Norberto Cerasale Morteo, en Salta, Argentina… https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Winter Break for the "Equitable Health" Blog Group... the blogs will not be updated on July 26, 27, 28, 29, and 30, 2026... We apologize for this, but we hope you understand that we deserve a break... We will return on July 31, God willing... Many thanks to all our readers and followers (whose numbers are constantly growing)... Until then... The Editor... "Equitable Health" Blog Group, owned by Víctor Norberto Cerasale Morteo, in Salta, Argentina... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Pause hivernale pour le groupe de blogs « Equitable Health »… Les articles ne seront pas mis à jour les 26, 27, 28, 29 et 30 juillet 2026… Nous vous prions de nous excuser pour ce désagrément, mais nous espérons que vous comprendrez que nous méritons bien une pause… Nous serons de retour le 31 juillet, si Dieu le veut… Un grand merci à tous nos lecteurs et abonnés (dont le nombre ne cesse de croître)… À bientôt… La rédaction… Le groupe de blogs « Equitable Health », propriété de Víctor Norberto Cerasale Morteo, à Salta, en Argentine… https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Winterpause für die Bloggruppe „Gerechte Gesundheit“ … Die Blogs werden am 26., 27., 28., 29. und 30. Juli 2026 nicht aktualisiert. Wir bitten um Entschuldigung und hoffen auf Ihr Verständnis, dass wir uns eine Auszeit verdient haben. Wir sind am 31. Juli wieder für Sie da, so Gott will. Vielen Dank an alle unsere Leser und Follower (deren Zahl stetig wächst). Bis dahin … Die Redaktion der Bloggruppe „Gerechte Gesundheit“, Inhaber: Víctor Norberto Cerasale Morteo, Salta, Argentinien. https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Зимний перерыв для блог-группы "Equitable Health"... блоги не будут обновляться 26, 27, 28, 29 и 30 июля 2026 года... Приносим свои извинения, но надеемся на ваше понимание, что мы заслужили перерыв... Мы вернемся 31 июля, если Бог даст... Большое спасибо всем нашим читателям и подписчикам (число которых постоянно растет)... До тех пор... Редактор... Блог-группа "Equitable Health", принадлежащая Виктору Норберто Серасале Мортео, Сальта, Аргентина... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ "इक्विटेबल हेल्थ" ब्लॉग ग्रुप के लिए विंटर ब्रेक... ब्लॉग 26, 27, 28, 29, और 30 जुलाई, 2026 को अपडेट नहीं किए जाएंगे... हम इसके लिए माफ़ी चाहते हैं, लेकिन हमें उम्मीद है कि आप समझेंगे कि हम एक ब्रेक के हकदार हैं... हम 31 जुलाई को वापस आएंगे, भगवान चाहेंगे... हमारे सभी रीडर्स और फॉलोअर्स (जिनकी संख्या लगातार बढ़ रही है) का बहुत-बहुत धन्यवाद... तब तक... एडिटर... "इक्विटेबल हेल्थ" ब्लॉग ग्रुप, जिसके मालिक विक्टर नॉरबर्टो सेरासले मोर्टेओ हैं, साल्टा, अर्जेंटीना में है... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Recesso de Inverno para o Grupo de Blogs "Saúde Equitativa"... os blogs não serão actualizados nos dias 26, 27, 28, 29 e 30 de Julho de 2026... Pedimos desculpa por isso, mas esperamos que compreendam que merecemos uma pausa... Regressaremos no dia 31 de Julho, se Deus quiser... Muito obrigado a todos os nossos leitores e seguidores (cujo número está em constante crescimento)... Até lá... A Equipa Editorial... Grupo de Blogs "Saúde Equitativa", propriedade de Víctor Norberto Cerasale Morteo, em Salta, Argentina... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Pausa invernale per il gruppo di blog "Equitable Health"... i blog non verranno aggiornati il 26, 27, 28, 29 e 30 luglio 2026... Ci scusiamo per questo, ma speriamo che comprendiate che ci meritiamo una pausa... Torneremo il 31 luglio, a Dio piacendo... Un sentito ringraziamento a tutti i nostri lettori e follower (il cui numero è in costante crescita)... A presto... Il Direttore... Gruppo di blog "Equitable Health", di proprietà di Víctor Norberto Cerasale Morteo, a Salta, Argentina... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ "ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழுவிற்கு குளிர்கால இடைவேளை... ஜூலை 26, 27, 28, 29, மற்றும் 30, 2026 ஆகிய தேதிகளில் வலைப்பதிவுகள் புதுப்பிக்கப்படாது... இதற்காக வருந்துகிறோம், ஆனால் எங்களுக்கு ஒரு இடைவேளை தேவை என்பதை நீங்கள் புரிந்துகொள்வீர்கள் என்று நம்புகிறோம்... எல்லாம் வல்ல இறைவனின் அருளால், ஜூலை 31 அன்று நாங்கள் திரும்புவோம்... எங்கள் வாசகர்கள் மற்றும் பின்தொடர்பவர்கள் அனைவருக்கும் மிக்க நன்றி (அவர்களின் எண்ணிக்கை தொடர்ந்து அதிகரித்து வருகிறது)... அதுவரை... ஆசிரியர்... "ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழு, விக்டர் நோர்பெர்டோ செராசேல் மோர்டியோவுக்குச் சொந்தமானது, சால்டா, அர்ஜென்டினா... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ “公平健康”博客组冬季休刊……博客将于2026年7月26日、27日、28日、29日和30日暂停更新……对此我们深表歉意，但希望您能理解我们需要休息……我们将于7月31日恢复更新，如果一切顺利……非常感谢所有读者和关注者（人数还在不断增长）……此致……编辑……“公平健康”博客组，由阿根廷萨尔塔省的维克托·诺贝托·塞拉萨莱·莫特奥所有…… https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/

Watch: ‘Robust’ Primary Care, Transparency Top Employers’ Reform Wish List

‘Robust’ Primary Care, Transparency Top Employers’ Reform Wish List | How Would You Fix It? https://kffhealthnews.org/health-industry/employer-health-insurance-elizabeth-mitchell-interview-pbgh/

The New Old Age

The New Old Age Paula Span explores the unprecedented challenges posed by a rapidly aging population. Beginning in April 2025, The New Old Age has been produced through a partnership between KFF Health News and The New York Times. https://kffhealthnews.org/series/the-new-old-age/

To Afford Aging in Place, Older Adults Turn to ‘Golden Girls’ Housing By Paula Span July 24, 202

https://kffhealthnews.org/aging/golden-girls-home-sharing-older-adults-colorado-pennsylvania/?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz-_PHwXS12kvLBTkAhKRXmOYA6ufFrexJ7CEO3r5P29S25Q8SgsXmNShT2HTsNjx4LWdyTehSE0HfOpKpRJALvk3tYHCsw&_hsmi=429996236&utm_content=429996236&utm_source=hs_email To Afford Aging in Place, Older Adults Turn to ‘Golden Girls’ Housing By Paula Span A growing network of home-sharing programs is helping people find compatible housemates. And demand is rising, driven by housing shortages, rising rents, and sales prices that affect both the old and the young.

States Start Their Medicaid Cuts

Republican Senator Bill Cassidy Talks Trump’s Tariffs, Health Reform, and RFK Jr.

Watch: GOP Senator Says Trump’s Tariffs Could Mean Safer Drugs — For a Price https://kffhealthnews.org/health-industry/bill-cassidy-interview-senate-trump-tariffs-drug-prices-rfk-promises/?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz-_Wx226JpzONcpLkqfMPIJZDOeICF0k7mjlWtcipN3FFmb_mE6icS4KPxhEgJMczjWXbRpXyVCMlxUgUpOWHBJUR3MGWQ&_hsmi=429996236&utm_content=429996236&utm_source=hs_email

A Shrinking Safety Net

Trump Team Pauses $1B in Medicaid Payments Over Suspected Fraud, 4.5M People Lost Food Assistance

How Are States Spending Opioid Settlement Cash? We Built a Database of Answers.

What You Need to Know About the Opioid Settlement Funds

Payback Tracking the Opioid Settlement Cash

Opioid manufacturers, distributors, and retailers are paying tens of billions of dollars in restitution to settle lawsuits about their role in the overdose epidemic, with little oversight on how the money is spent. We’re tracking how state and local governments use — or misuse — the cash. https://kffhealthnews.org/opioid-settlements/?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz--_9kve8_LMvqaxN8D_kFw9qUmaA5QFAStqz1LyhlU6gk34re9z-QkZ-0enH6nHYEm6Iamz7yy19r0arRZQodc_z-1pMQ&_hsmi=429996236&utm_content=429996236&utm_source=hs_email

American Scientists See Prosecutions as Part of Federal Campaign Against Them By Katheryn Houghton and Arthur Allen July 22, 2026

https://kffhealthnews.org/public-health/american-scientists-virologist-charges-mpox-samples-rocky-mountain-laboratories/?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz-9Xkfc1k6K-sBq4Sz5lWXYI-V6yA5-ES4Sa-MW5Qhm9VmgErA2o7MidKlsZeRzcbkrj_dyNb1dGsV_thOURb7Rc52exuA&_hsmi=429996236&utm_content=429996236&utm_source=hs_email American Scientists See Prosecutions as Part of Federal Campaign Against Them By Katheryn Houghton and Arthur Allen Federal officials charged two virologists they stopped en route from an African disease outbreak with violating import rules. But scientists tell KFF Health News the inactivated samples they carried posed no threat to the public, and they characterize the arrests as part of a government harassment campaign.

Violence Repeatedly Erupts at Dementia Care Facilities Despite Warnings, Inspections Show By Jordan Rau July 20, 2026 +... +... +...

https://kffhealthnews.org/health-industry/dementia-violence-assaults-nursing-homes-assisted-living-california-minnesota-virginia/ Nursing homes and assisted living facilities can be fertile ground for violence between residents with dementia, including fatal assaults. A KFF Health News examination of health reports and court records shows how warning signs are missed and safeguards fall short. Sam Ato Timaloa, a paroled sex offender who also served time for attempted murder, had dementia and an acute intolerance of noise — especially from roommates at Sunrise Post Acute, a nursing home in Banning, California. Over four months in 2025, a state investigative report found, Sunrise switched Timaloa’s room eight times, the last into one occupied by Attilio Cecchetto, 92, a retired tile installer whose dementia led him to frequently moan, mumble, and yell. Pregnant Woman’s Roadside Death Triggers Push To Reopen Mississippi Delta Hospital By Gwen Dilworth, Mississippi Today July 20, 2026 https://kffhealthnews.org/rural-health/rural-mississippi-delta-hospital-desert-pregnant-woman-dies-emergency-services/ The deaths of Harmony Ball-Stribling and her unborn daughter five years ago have galvanized local leaders determined to reopen a Mississippi Delta hospital. But once a rural community loses a hospital, bringing it back can be nearly impossible. BELZONI, Miss. — Harmony Ball-Stribling’s path to pregnancy had been turbulent, from an endometriosis diagnosis to an arduous in vitro fertilization process and sky-high blood pressure. But as her due date approached in the summer of 2021, her health improved and those storm clouds seemed to scatter. A Deloitte-Run System Denied Medicaid Benefits for Michigan’s Disabled. Now Trump’s Law Piles On. By Rachana Pradhan, Samantha Liss, and Kate Wells July 21, 2026 Marie Noon takes eight medications a day. One keeps her heart rate from spiking to avoid a stroke. One prevents debilitating headaches. Another ensures she doesn’t retain excess fluid. Complex computer systems that decide whether people, including the disabled, get Medicaid benefits have a history of errors. Now changes to comply with Trump’s signature One Big Beautiful Bill Act are inundating those systems.

Trump’s Personnel Agency Says It Will Remove Some Identifying Info as It Sweeps Up Medical Records By Amanda Seitz, Maia Rosenfeld, and Darius Tahir July 22, 2026

https://kffhealthnews.org/insurance/trump-opm-federal-workers-medical-records-data-privacy-pseudonymize/ The Office of Personnel Management said it will “pseudonymize” medical records it collects on more than 8 million people — federal workers and retirees, and their family members. Democrats and employee unions say the agency’s move is an overreach. The Trump administration is forging ahead with a controversial plan to collect the medical records of millions of federal workers and retirees, as well as their family members.

FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds August 25, 2026

https://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-fda-led-patient-focused-drug-development-meeting-nonhealing-chronic-wounds?utm_medium=email&utm_source=govdelivery Public Meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds On August 25, 2026, FDA is hosting a hybrid public meeting on Patient-Focused Drug Development (PFDD) for Nonhealing Chronic Wounds. This meeting will provide FDA and other key stakeholders, including medical product developers, health care providers, and academic researchers, the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial. There will be three sessions focused on: (1) health effects and daily impacts, (2) current approaches to treatment, and (3) perspectives on clinical trials. For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience. Panelists are also welcome to participate in the facilitated discussion. Meeting Logistics and Registration Date: August 25, 2026 Time: 10:00 a.m. – 4:30 p.m. ET Registration: https://www.fda.gov/pfddchronicwounds Location: Attend In Person or Online Virtual: Via Webcast In Person: FDA White Oak Campus, 10903 New Hampshire Ave, Building 31, Room 1503, Silver Spring, MD 20993 Panelists Patients or care partners interested in providing comments as part of the panel discussion are asked to indicate their interest when they register for the meeting by July 31, 2026. A member of our PFDD Staff will contact them via email. Panelists will be confirmed prior to the meeting and will be invited to a brief one-on-one call with our team to help prepare for their role in the discussion.

FDA Roundtable: Strengthening the Supply Chain for Blood Manufacturing - September 29, 2026 September 29, 2026

https://www.fda.gov/vaccines-blood-biologics/workshops-meetings-conferences-biologics/fda-roundtable-strengthening-supply-chain-blood-manufacturing-september-29-2026-09292026?utm_medium=email&utm_source=govdelivery

FDA SCIENTIFIC PUBLIC WORKSHOP: NEXT-GENERATION SEQUENCING FOR ADVENTITIOUS AGENT DETECTION IN BIOLOGICS September 23, 2026

https://www.fda.gov/news-events/otp-events-meetings-and-workshops/fda-scientific-public-workshop-next-generation-sequencing-adventitious-agent-detection-biologics?utm_medium=email&utm_source=govdelivery

Cellular, Tissue, and Gene Therapies Advisory Committee July 30, 2026 Meeting Announcement- UPDATED INFORMATION (as of 7/16/2026) July 30, 2026

https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-30-2026-meeting-announcement-updated?utm_medium=email&utm_source=govdelivery

Cellular, Tissue, and Gene Therapies Advisory Committee July 29, 2026 Meeting Announcement- UPDATED INFORMATION (as of 7/16/2026) July 29, 2026

https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated

Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application Guidance for Industry

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-flexibilities-developing-human-cellular-and-gene-therapy?utm_medium=email&utm_source=govdelivery

Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing June 2026

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/leveraging-prior-knowledge-development-human-gene-therapy-products-incorporating-genome-editing?utm_medium=email&utm_source=govdelivery

Getting a Radiation Emitting Product to Market: Frequently Asked Questions

https://www.fda.gov/radiation-emitting-products/electronic-product-radiation-control-program/getting-radiation-emitting-product-market-frequently-asked-questions?utm_medium=email&utm_source=govdelivery Receso Invernal del grupo de blog´s de "salud equitativa"... los días 26, 27, 28, 29, y 30 de julio de 2026, los blog´s no se actualizarán... pedimos disculpas por ello, pero esperamos sepan entender que merecemos un descanso... regresaremos el 31 de julio si Dios lo permite... muchas gracias a todos los lectores y seguidores (que cada vez son más)... hasta entonces... El editor... Grupo de blog´s de “salud equitativa”, cuyo titular es Víctor Norberto Cerasale Morteo, en Salta, Argentina… https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Winter Break for the "Equitable Health" Blog Group... the blogs will not be updated on July 26, 27, 28, 29, and 30, 2026... We apologize for this, but we hope you understand that we deserve a break... We will return on July 31, God willing... Many thanks to all our readers and followers (whose numbers are constantly growing)... Until then... The Editor... "Equitable Health" Blog Group, owned by Víctor Norberto Cerasale Morteo, in Salta, Argentina... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Pause hivernale pour le groupe de blogs « Equitable Health »… Les articles ne seront pas mis à jour les 26, 27, 28, 29 et 30 juillet 2026… Nous vous prions de nous excuser pour ce désagrément, mais nous espérons que vous comprendrez que nous méritons bien une pause… Nous serons de retour le 31 juillet, si Dieu le veut… Un grand merci à tous nos lecteurs et abonnés (dont le nombre ne cesse de croître)… À bientôt… La rédaction… Le groupe de blogs « Equitable Health », propriété de Víctor Norberto Cerasale Morteo, à Salta, en Argentine… https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Winterpause für die Bloggruppe „Gerechte Gesundheit“ … Die Blogs werden am 26., 27., 28., 29. und 30. Juli 2026 nicht aktualisiert. Wir bitten um Entschuldigung und hoffen auf Ihr Verständnis, dass wir uns eine Auszeit verdient haben. Wir sind am 31. Juli wieder für Sie da, so Gott will. Vielen Dank an alle unsere Leser und Follower (deren Zahl stetig wächst). Bis dahin … Die Redaktion der Bloggruppe „Gerechte Gesundheit“, Inhaber: Víctor Norberto Cerasale Morteo, Salta, Argentinien. https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Зимний перерыв для блог-группы "Equitable Health"... блоги не будут обновляться 26, 27, 28, 29 и 30 июля 2026 года... Приносим свои извинения, но надеемся на ваше понимание, что мы заслужили перерыв... Мы вернемся 31 июля, если Бог даст... Большое спасибо всем нашим читателям и подписчикам (число которых постоянно растет)... До тех пор... Редактор... Блог-группа "Equitable Health", принадлежащая Виктору Норберто Серасале Мортео, Сальта, Аргентина... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ "इक्विटेबल हेल्थ" ब्लॉग ग्रुप के लिए विंटर ब्रेक... ब्लॉग 26, 27, 28, 29, और 30 जुलाई, 2026 को अपडेट नहीं किए जाएंगे... हम इसके लिए माफ़ी चाहते हैं, लेकिन हमें उम्मीद है कि आप समझेंगे कि हम एक ब्रेक के हकदार हैं... हम 31 जुलाई को वापस आएंगे, भगवान चाहेंगे... हमारे सभी रीडर्स और फॉलोअर्स (जिनकी संख्या लगातार बढ़ रही है) का बहुत-बहुत धन्यवाद... तब तक... एडिटर... "इक्विटेबल हेल्थ" ब्लॉग ग्रुप, जिसके मालिक विक्टर नॉरबर्टो सेरासले मोर्टेओ हैं, साल्टा, अर्जेंटीना में है... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Recesso de Inverno para o Grupo de Blogs "Saúde Equitativa"... os blogs não serão actualizados nos dias 26, 27, 28, 29 e 30 de Julho de 2026... Pedimos desculpa por isso, mas esperamos que compreendam que merecemos uma pausa... Regressaremos no dia 31 de Julho, se Deus quiser... Muito obrigado a todos os nossos leitores e seguidores (cujo número está em constante crescimento)... Até lá... A Equipa Editorial... Grupo de Blogs "Saúde Equitativa", propriedade de Víctor Norberto Cerasale Morteo, em Salta, Argentina... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ Pausa invernale per il gruppo di blog "Equitable Health"... i blog non verranno aggiornati il 26, 27, 28, 29 e 30 luglio 2026... Ci scusiamo per questo, ma speriamo che comprendiate che ci meritiamo una pausa... Torneremo il 31 luglio, a Dio piacendo... Un sentito ringraziamento a tutti i nostri lettori e follower (il cui numero è in costante crescita)... A presto... Il Direttore... Gruppo di blog "Equitable Health", di proprietà di Víctor Norberto Cerasale Morteo, a Salta, Argentina... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ "ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழுவிற்கு குளிர்கால இடைவேளை... ஜூலை 26, 27, 28, 29, மற்றும் 30, 2026 ஆகிய தேதிகளில் வலைப்பதிவுகள் புதுப்பிக்கப்படாது... இதற்காக வருந்துகிறோம், ஆனால் எங்களுக்கு ஒரு இடைவேளை தேவை என்பதை நீங்கள் புரிந்துகொள்வீர்கள் என்று நம்புகிறோம்... எல்லாம் வல்ல இறைவனின் அருளால், ஜூலை 31 அன்று நாங்கள் திரும்புவோம்... எங்கள் வாசகர்கள் மற்றும் பின்தொடர்பவர்கள் அனைவருக்கும் மிக்க நன்றி (அவர்களின் எண்ணிக்கை தொடர்ந்து அதிகரித்து வருகிறது)... அதுவரை... ஆசிரியர்... "ஈக்விடபிள் ஹெல்த்" வலைப்பதிவுக் குழு, விக்டர் நோர்பெர்டோ செராசேல் மோர்டியோவுக்குச் சொந்தமானது, சால்டா, அர்ஜென்டினா... https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/ “公平健康”博客组冬季休刊……博客将于2026年7月26日、27日、28日、29日和30日暂停更新……对此我们深表歉意，但希望您能理解我们需要休息……我们将于7月31日恢复更新，如果一切顺利……非常感谢所有读者和关注者（人数还在不断增长）……此致……编辑……“公平健康”博客组，由阿根廷萨尔塔省的维克托·诺贝托·塞拉萨莱·莫特奥所有…… https://wwweldispreciau.blogspot.com/ https://eldispensador.blogspot.com/ https://saludequitativa.blogspot.com/ https://herenciageneticayenfermedad.blogspot.com/ https://elbiruniblogspotcom.blogspot.com/

FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials August 27, 2026

https://www.fda.gov/drugs/news-events-human-drugs/fda-virtual-workshop-digital-health-technologies-and-statistical-considerations-digitally-derived